Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated. All patients available for testing showed increased ultraviolet A-sensitivity (n = 5); patch testing revealed no type IV allergies (n = 6). In 5 patients intravenous DTIC was replaced by oral temozolomide, and no phototoxicity occurred. Temozolomide may represent an alternative for patients with DTIC-induced phototoxic skin reactions.
Treudler
Regina
R
Department of Dermatology, Charité-University Medical School Berlin, Campus Benjamin Franklin, Berlin, Germany. regina.treudler@charite.de
Georgieva
Juliana
J
Geilen
Christoph C
CC
Orfanos
Constantin E
CE
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017484:Dermatitis, Phototoxic / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide